Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.
US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to treat triple-negative breast cancer (TNBC).
TapImmune has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer.
Peter Hoang loves being on the cutting-edge, and he believes Jacksonville-based TapImmune, Inc., which named him president and CEO Sept. 25, is there.
There are three trials that are really going to drive value for this company over the coming 24 months.
TapImmune Inc. has a new chief executive officer. Peter Hoang, the former head of business development and strategy at Bellicum Pharmaceuticals, will take over for CEO Glynn Wilson, who has been reappointed to the position of chairman of the board of directors.
Second Quarterly Call Earnings Call Transcript
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.